Bioventus Inc. (BVS)
2025-06-28 | 2025-03-29 | 2024-09-28 | 2024-06-29 | |
|---|---|---|---|---|
| Net sales | 147,660 | 123,876 | 138,964 | 151,217 |
| Cost of sales (including depreciation and amortization of 10,603, 11,021, 20,868 and 21,046, respectively) | 45,570 | 40,820 | 45,413 | 47,578 |
| Gross profit | 102,090 | 83,056 | 93,551 | 103,639 |
| Loss on disposals | -1 | -81 | - | - |
| Depreciation and amortization | 1,439 | 1,593 | 2,065 | 2,064 |
| Change in fair value of contingent consideration | - | - | 483 | 300 |
| Impairment of assets | - | - | 2,031 | 31,870 |
| Research and development expense | 3,172 | 3,011 | 3,808 | 3,988 |
| Selling, general and administrative expense | 79,110 | 73,502 | 81,090 | 94,785 |
| Operating income (loss) | 18,368 | 4,869 | 4,074 | -29,368 |
| Other expense, net | -561 | -777 | 626 | -159 |
| Interest expense, net | -7,494 | -7,509 | -9,532 | -9,924 |
| Other expense | -8,055 | -8,286 | -8,906 | -10,083 |
| Income (loss) before income taxes | 10,313 | -3,417 | -4,832 | -39,451 |
| Income tax expense (benefit), net | 1,041 | -95 | 589 | -7,339 |
| Net loss from continuing operations | - | - | -5,421 | -32,112 |
| Net income (loss) | 9,272 | -3,322 | -5,421 | -32,112 |
| (income) loss attributable to noncontrolling interest | 1,813 | -685 | - | - |
| Loss attributable to noncontrolling interest - continuing operations | - | - | -597 | -8,120 |
| Net income (loss) attributable to bioventus inc | 7,459 | -2,637 | -4,824 | -23,992 |
| Basic (in shares) | 66,500,433 | 66,008,683 | 65,258,427 | 64,056,759 |
| Diluted (in shares) | 68,536,759 | 66,008,683 | 65,258,427 | 64,056,759 |
| Loss per share of class a common stock, basic (in dollars per share) | 0.11 | -0.04 | -0.07 | -0.37 |
| Loss per share of class a common stock, diluted (in dollars per share) | 0.11 | -0.04 | -0.07 | -0.37 |